For decades, scientists have struggled to explain why some people with early signs of Alzheimer’s never go on to develop dementia, while others quickly decline. A new study from Harvard Medical School may provide the missing piece of the puzzle: lithium deficiency in the brain.
A Decade of Research
The findings, published in Nature after ten years of investigation, show that lithium is a natural element in the brain that helps preserve cognitive function. Researchers discovered that lithium levels fall sharply in the earliest stages of Alzheimer’s, often before symptoms begin. In both human brain tissue and blood samples, lithium was the only metal that consistently showed dramatic changes between healthy individuals, those with mild cognitive impairment, and those with advanced Alzheimer’s.
Senior author Bruce Yankner, professor of genetics and neurology at Harvard, explained, “The idea that lithium deficiency could be a cause of Alzheimer’s disease is new and suggests a different therapeutic approach.”
How Lithium Loss Drives Alzheimer’s
The research showed that as amyloid beta plaques form in the brain, they trap lithium, reducing its availability. This depletion triggers a chain reaction across all major brain cell types. In mouse models, lithium loss caused inflammation, loss of synapses and axons, breakdown of protective myelin, and accelerated memory decline.
One critical mechanism was the activation of microglia, immune cells in the brain. Without enough lithium, these cells could not clear amyloid properly, leading to faster buildup of plaques. The result was damage that mimicked the hallmarks of Alzheimer’s.
Lithium Orotate: A Promising Form
While traditional lithium medications like lithium carbonate are used to treat bipolar disorder, they require high doses that can be toxic, especially for older adults. The Harvard team identified lithium orotate, a compound that avoids being trapped by amyloid plaques, as especially effective.
In mice, lithium orotate worked at doses one-thousandth as strong as standard psychiatric medications. It restored memory, repaired damaged neurons, and even prevented Alzheimer’s-like disease when given early. Mice treated for nearly their entire adult lives showed no signs of toxicity.
“What impresses me the most about lithium is the widespread effect it has on the various manifestations of Alzheimer’s. I really have not seen anything quite like it all my years of working on this disease,” Yankner said.
What Experts Are Saying
Outside experts are cautiously optimistic. Dr. Manisha Parulekar, director of geriatrics at Hackensack University Medical Center, noted that the research takes a more holistic view of the disease. “For years, the fight against Alzheimer’s has been dominated by a single-target approach, focusing almost exclusively on clearing amyloid plaques. This study suggests restoring balance to a natural element could impact all the major hallmarks of the disease.”
Dr. Peter Gliebus, a neurologist at Marcus Neuroscience Institute, agreed the results were promising. He explained that lithium deficiency could serve as an early biomarker for Alzheimer’s, allowing doctors to identify patients at higher risk before symptoms appear.
Looking Toward Prevention and Treatment
If confirmed in humans, this research could transform Alzheimer’s care. Measuring lithium levels might become part of routine screenings, and low-dose lithium orotate could be tested as a preventative treatment. Importantly, the compound seems capable of both protecting healthy brain cells and reversing damage in diseased ones.
Still, the scientists stress caution. “You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial,” Yankner warned.
The next step will be clinical trials to determine safe and effective doses for older adults. Policymakers and funding agencies could play a critical role in speeding up this research, given the urgent need for better treatments.
A Potential Breakthrough in Alzheimer’s Care
Alzheimer’s disease affects up to 400 million people worldwide, with treatments currently limited to easing symptoms. The idea that lithium, an inexpensive and widely available mineral, could be used to prevent or even reverse cognitive decline represents a dramatic shift.
As Yankner summed up, “My hope is that lithium will do something more fundamental than anti-amyloid or anti-tau therapies, not just lessening but reversing cognitive decline and improving patients’ lives.”
